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ABSTRACT 
 
 
 
 Alzheimer’s disease (AD) is a neurodegenerative disease thought to be caused by the 
abnormal production and/or low clearance of neurotoxic amyloid-beta.  Using transgenic mice 
that mimic AD, this project measured whether AD mice treated with a neurotrophic factor 
mimetic previously shown to increase human neuronal survival in vitro improves mouse 
behavior.  A Morris water-maze swimming test that requires a functional hippocampus was used 
to compare learning behavior in WT and AD mice. AD mice took on average 25 seconds to 
locate the hidden platform on the final day of testing, while WT located the platform in roughly 
10 seconds (p = 0.05).  Treated AD mice showed a 19% decrease (p < 0.01) relative to untreated 
AD mice in the distance traveled to locate a marked platform, and a 24% decrease  in the 
distance traveled to locate an unmarked platform. 
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BACKGROUND 
 
 
Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of dementia in the U.S., causing 
deficiencies in logic, memory, and behavior. Its prevalence has been increasing, with 13% of 
Americans over the age of 65 currently diagnosed with AD, making it the fifth leading cause of 
death among that age group (Alzheimer’s Facts, 2010). AD was first characterized in 1901 in a 
51 year-old woman (Auguste Deter) who complained of a lost self-identity. She was cared for by 
a German physician, Dr. Alois Alzheimer, who characterized her dementia, and later in 1906 for 
the brain autopsy showed the existence of the main hallmark cellular features of the disease: 
extracellular senile plaques and intracellular neurofibrillary tangles (Alzheimer’s Foundation of 
America, 2010). Up until now, a post-mortem brain autopsy was the most conclusive method of 
diagnosing the disease (Progress Report, 2009; Alzheimer’s Foundation of America, 2010). 
 
AD Symptoms 
 AD symptoms tend to worsen with age. Early on, patients experience impaired memory 
such as problems recalling names, recent activities, placement of objects, as well as a general 
disorientation. Other warning signs include withdrawal from social events, changes in 
personality, irritability, and apathy (Progress Report, 2009; Alzheimer’s Facts, 2010). As the 
disease progresses, there is a further decline in cognitive and functional abilities. Patients begin 
to struggle with speaking, swallowing, making judgments, or recognizing family members or 
loved ones (Alzheimer’s Foundation of America, 2010). Difficulty with easy motor tasks, such 
as using a spoon or putting on clothes, becomes more evident. Some patients who develop 
psychotic symptoms experience auditory and/or visual hallucinations, and sensory impairment 
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(Progress Report, 2009; Alzheimer’s Foundation of America, 2010).  Symptoms typically begin 
to appear between the ages of 60–70, but can appear as early as the 40’s for early on-set cases.  
Once diagnosed, patients typically live another 8-10 years.  Death usually results from 
pneumonia resulting from complications of being immobile. 
 
AD Cellular Pathology 
  At the cellular level, specific neurons that make up the memory control centers of the 
brain (the entorhinal cortex and the hippocampus) begin to lose their connections and die due to 
disruption of communication, metabolism, and repair (Progress Report, 2009).  Major damage is 
observed in the temporal region, and with further progression the cortex (the brain region 
responsible for communication and reasoning) also becomes damaged (Figure-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: Photograph of a Normal Human Brain (upper) and an AD Brain 
(lower). Note the appearance of areas of the AD brain with loss of gray and 
white matter. ((Sanders, 2011) 
 
 
The two hallmark pathological features of AD are: 1) intracellular neurofibrillary tangles 
(NFTs), interwoven fibers caused by abnormally hyper-phosphorylated tau proteins, 2) 
extracellular senile plaques, aggregations of over-expressed beta-amyloid (Aβ) protein, and 3) 
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congophilic angiopathy, the formation of amyloid depositions in the blood vessel walls of the 
central nervous system (Progress Report, 2009).  
 
AD Diagnosis 
  In the case of a progressive, irreversible disease, it is vital that an early diagnosis is made 
so that the affected individuals can make plans while they still have cognitive function.  Until 
now, there has not been a conclusive method of AD diagnosis besides the standard post-mortem 
brain autopsy (Progress Report, 2009; Alzheimer’s Foundation of America, 2010). However, 
clinicians now use a combination of assessments (Figure-2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure-2: Diagnosis Scheme for Mental Dysfunction. The assessment begins with information 
gathered from previous family history or talking to the patient, with special attention to any 
dependence they have on others for their activities of daily living (ADL), an indicator of mental 
status (MS). Medical conditions such as seizures, hallucinations, and risk of stroke are also 
important features in the diagnosis (Knopman et al., 2003). 
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Mental assessment typically begins by studying patient and family medical histories, as 
well as periodic physical examinations to assess a patient’s level of memory and language 
ability. Although it not useful for distinguishing AD from other forms of dementia, the Mini 
Mental State Examination (MMSE) has been the most prevalent screening test for dementia due 
to its ease and rapidity (Progress Report, 2009).  Unfortunately, these assessments neglect to 
account for mild changes in cognition, but instead diagnose moderate to severe AD.  Research 
has indicated that AD begins to invade the brain long before clinical symptoms manifest. Thus, 
much research has focused on developing sophisticated protocols to detect early AD.   
The written MMSE has now been remodeled into a number of computer-based 
examinations with automated scoring (Saxton et al., 2009). A collaborative effort of various US 
academic research groups, known as the Alzheimer’s Disease Neuroimaging Initiative (ADNI), 
is performing multiple longitudinal studies to identify an AD biomarker only observed in the 
CSF of AD patients (Progress Report, 2009). Biomarker levels are being assessed using multiple 
brain imaging technologies, including PET amyloid imaging, and diffusion, functional, and 
spectroscopic MRIs.  PET imaging with florbetapir has been shown to identify up to 96% of AD 
cases as later confirmed by post-mortem brain autopsies (Clark et al., 2011). In addition, the 
plasma levels of Aβ have been shown to decrease with AD, presumably in response to its 
sequestration in the brain as the senile plaques form, potentially providing an AD blood test 
(Yaffe et al., 2011). 
 
AD Risk Factors 
  The largest non-hereditary risk factor of AD is advancing age. Due to reasons not fully 
understood, upon reaching the age of 65 the chances of developing AD doubles every 5 years, 
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reaching nearly 50% by the age of 85 (Alzheimer’s Facts, 2010). The average age of the U.S. 
population is increasing, and the average number of people living over 100 years is expected to 
be 15 times greater in 50 years (Progress Report, 2009). Research suggests that as neurons age, 
there is increased mitochondrial fission, a larger reliance to fats and amino acids (instead of the 
usual glucose) for energy production, and an increase in insulin-like growth-factor-1 (IGF-1), a 
hormone responsible for cell growth (Yao et al., 2009; Kadish et al., 2009). Each of these 
cellular ageing effects also boosts Aβ production. 
Genetic mutations have also been shown to increase the production of toxic Aβ as a result 
of higher amyloid precursor protein (APP) processing. Early-onset familial AD (FAD) has been 
strongly linked with the following three gene mutations: amyloid precursor protein (APP) on 
chromosome-21, presenilin-1 (PS-1) on chromosome-14, and presenilin-2 (PS-2) on 
chromosome-1 (Progress Report, 2009; Alzheimer’s Facts, 2010). A fourth gene mutation known 
to increase AD risk is Apolipoprotein E (ApoE) on chromosome-19. Other factors implicated to 
increase AD risk include head traumas and cardiovascular disease.   
 
AD Prevalence 
Accounting for roughly 60-80% of all dementia cases in 2011, AD was classified as the 
most common type of dementia in 2011. Approximately 5.4 million Americans currently have 
AD.  Of this number, 45% are 85 and older, 45% are age 75-84, and 6% are 65-74 years of age. 
A significant 13% (1 in 8) Americans aged 65 and older have AD (Herbert et al. 2003). Globally, 
Alzheimer’s Disease International (ADI) estimates that 30 million people had AD in 2008, and a 
projected 100 million will be affected by 2050 (Alzheimer’s Disease International, 2010).   
Annually, 4.6 million new cases of AD (one new case every seven seconds) are diagnosed 
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(Alzheimer’s Facts, 2011).  Outside the U.S., the trend of increasing AD prevalence with 
increased age has also been verified for Europe, the Middle East/North Africa, Asia, and Sub-
Saharan Africa.  For all populations (Figure-3), AD is predicted to increase in prevalence more 
rapidly in low to middle income countries (red), than high income nations (brown).  
 
 
Figure- 3:  Estimates for AD Prevalence According to Income.  The number 
of individuals affected by AD dementia in low and middle income countries 
(red) is more than twice that of high income countries (brown). By 2050 the low 
and middle income country populations affected by AD will be three times those 
affected in high income countries. (Alzheimer’s Disease International, 2010). 
 
Almost two-thirds of all Americans living with the disease are women. Of those living 
with Alzheimer’s over the age of 65, 3.4 million are women and 1.8 million are men (Herbert et 
al., 2003; Shriver, 2010). Further research showed that the difference in proportion is likely due 
to the higher average life expectancy of women. When incidence was measured using age-
specific criteria, a significant difference between genders did not exist (Bachman et al. 1993, 
Fillenbaum et al., 1998; Fitzpatrick et al., 2004; Herbert et al., 2001; Kukull et al., 2002).  
Researchers have also studied the difference in incidence of AD among ethnic groups in 
the U.S.  It was found that the majority of people living with AD are non-Hispanic whites. 
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However, above the age of 75, African-Americans and Hispanics are, respectively, 2.0 and 1.5 
times more likely to get AD (Figure-4) (Gurland et al. 1999; Potter et al., 2009). This difference 
can potentially be attributed to disparities in socioeconomic backgrounds, such as lower 
education levels, increased incidence of diabetes and high blood pressure, or other 
characteristics.  
 
 
 
 
 
 
 
 
 
Figure-4: AD Prevalence by Race.  Shown are the proportions of people aged 
65 and older with Alzheimer’s disease and other dementias by race/ethnicity.  
(Alzheimer’s Facts & Figures, 2011) 
 
The level of education is also associated with AD prevalence. It was found that higher 
years of education correlate with a decreased probability of developing dementia (Stern et al., 
1994; Evans et al., 1997; Gurland et al., 1999; Kulkull et al. 2002; Evans et al., 2003; Fitzpatrick 
et al., 2004; Plassman et al., 2007). Researchers speculate that additional education may allow 
for the development of a “cognitive reserve,” which enables individuals to better cope with the 
physiological effects of AD (Roe et al., 2007; Stern et al., 2006). It is also possible that this 
difference may simply be due to an overall greater risk for disease and limited medical care for 
lower socioeconomic groups (McDowell et al., 2007).  
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As the average life expectancy continues to increase due to advances in medicine and the 
projected betterment of social and environmental conditions, the incidence of Alzheimer’s is also 
expected to increase. By the year 2030, the U.S. population above 65 years is predicted to 
double. These estimated 71 million older Americans will make up roughly 20 percent of the total 
population. As depicted in Figure-5, with this increase in the number of older Americans, the 
number of individuals affected by AD will reach roughly 13.2 million by the year 2050.  
 
 
 
 
 
 
 
 
 
Figure-5: Projected Incidence of Alzheimer’s Disease from 2000-2050.  The 
number of individuals in the U.S. diagnosed with AD is projected to reach 13.2 
million by 2050.  (Alzheimer’s Facts & Figures, 2011) 
 
AD Therapies 
Currently, there are no treatments available to stop or reduce brain deterioration in AD. 
However, five drugs have been approved by the U.S. Food and Drug Administration (FDA) 
which temporarily slow the worsening of symptoms.  These drugs are effective in about half the 
individuals who use them, and remain effective for only about 6-12 months. The 5 approved 
drugs fall into two classes:  1) those that inhibit acetylcholinesterase, decreasing the degradation 
of acetylcholine in the synapse increasing its levels there, and 2) inhibitors of NMDA (N-methyl-
 13 
D-aspartate) receptor, which reduce the levels of excitotoxic glutamate in the synapse increasing 
memory and learning. The acetylcholinesterase inhibitors include Donepezil (Aricept, treats all 
stages), Galantamine (Razadyne, treats mild to moderate AD), Rivastigmine (Exelon, mild to 
moderate AD) and Tacrine (Cognex, mild to moderate AD).  The remaining FDA approved 
drug, Memantine (Namenda), is the only NMDA inhibitor, and is used to treat moderate to 
severe AD. As a glutamate regulator, Memantine works by partially blocking NMDA receptors 
on the cell surface, thus preventing excitotoxic glutamate from binding the receptor to induce 
cell damage (Alzheimer’s Association, 2012).  Several non-drug therapies have also been 
developed which aid in limiting memory loss, and correcting behavioral and sleep changes. Still, 
all current therapies work to mask AD symptoms rather than treat the underlying disease.   
Several national and international research associations are dedicated to finding an AD 
cure, including the NIA Division of Neuroscience Translational Research Platform and 
Alzheimer’s Disease Centers, the Genetics of Alzheimer’s Disease Data Storage Site, the 
National Alzheimer’s Coordinating Center, and the National Cell Repository for Alzheimer’s 
Disease (Alzheimer’s Association, 2012).  Much of the current research focuses on trying to treat 
the disease mechanism, not just the symptoms. Drugs have been created to alter major AD 
targets such as tau protein, Aβ, insulin resistance, and inflammation.  Other treatments approved 
for non-Alzheimer’s disorders, such as nonsteroidal anti-inflammatory drugs (NSAIDS), anti-
depressants, immune-modulatory polypeptide glatiramer (multiple sclerosis treatment), sildenafil 
(Viagra
®
), and antipsychotics, have also been tested. A recent study showed that the cancer drug 
exarotene (Targretin) was capable of improving memory and reversing signs of Alzheimer’s in 
mouse brains within 72 hours. Bexarotene was approved by the FDA in 1999 for treating 
cutaneous T-cell lymphoma, however research later found that it also turns on a gene that makes 
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ApoE, a naturally occurring neuronal protein that facilitates the proteolytic degradation and 
removal of toxic Aβ, so Bexarotene may also have AD applications (Cramer et al., 2012; Jiang et 
al., 2008). 
Though the search continues, researchers predict that science may soon find a solution, 
and that patients may soon require a drug cocktail that targeting several processes to eliminate 
the disease. Cocktails will likely include drugs that block the synthesis of new Aβ (i.e. Merck’s 
gamma-secretase inhibitor), drugs that remove existing Aβ (i.e. Elan Pharmaceuticals Aβ 
vaccines), and drugs that regrow neurons (i.e. using neuronal stem cells or neurotrophic factors, 
see below).  Among the numerous studies occurring, an estimated 75-100% are entering human 
clinical trials. 
 
Socioeconomic Toll 
As the number of individuals affected by AD continues to grow, the projected 
socioeconomic toll will continue to rise. Although medical care has improved over the last 8 
years, and death due to many diseases has decreased, death caused by AD has increased by more 
than 66% (Figure-6), leaving AD as the fifth leading cause of death for those aged 65 or older in 
the U.S. 
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Figure-6: Changes in Causes of Death for All Ages from 2000-2008(All 
Ages).  Note the 66% increase in AD (purple) compared to the decline in stroke, 
prostate cancer, breast cancer, heart disease, and HIV. (Alzheimer’s Facts, 2010) 
 
As stated by Harry John, President and CEO of the Alzheimer’s Association, “The scale 
of the Alzheimer’s public health crisis is clear. As many as 5.4 million Americans are living with 
Alzheimer’s today, with an economic toll of $183 billion per year” (Alzheimer’s Association, 
2012).  In 2010, globally the economic cost of dementia was an estimated $604 billion (USD) 
per year. This value includes both paid and unpaid care, as well as the direct costs of social and 
medical care. Of this value, medical care makes up a mere 16 percent. Although roughly 15 
million Americans provide unpaid care for AD individuals, the cost of AD healthcare, hospice, 
and long-term care is expected to increase to $1.1 trillion by 2050. 
 
Alzheimer’s Cell Death Mechanism, Amyloid Cascade Hypothesis 
At the cellular level, AD is characterized by severe neuronal loss and degradation 
primarily within the outer layers of the cerebral cortex. The temporal and frontal lobes are the 
first to be affected, followed by the parietal and occipital lobes. During this time of neuronal 
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loss, other cellular AD hallmarks also develop, including the formation of extracellular Aβ senile 
plaques, the formation of intracellular tau neurofibrillary tangles (NFTs), and synaptic and 
neuronal loss (Selkoe, 2001; Masters et al., 2006).  These hallmarks provide a premise for the 
most widely accepted hypothesis for AD pathogenesis, the Amyloid Cascade Hypothesis (ACH). 
According to the ACH, AD begins with the extracellular formation and eventual deposition of 
neurotoxic amyloid beta (Aβ), a 40-42 amino acid peptide derived from the proteolytic cleavage 
of amyloid precursor protein (APP) (Cappai & White, 1999; Selkoe, 2001; Masters et al., 2006; 
Crews and Masliah, 2010). The senile plaques formed often aggregate in regions involved in 
memory and cognition, and have been implicated in the disruption of long term potentiation, the 
accumulation of hyper-phosphorylated non-functional tau protein, and the generation of cellular 
reactive oxidative stress (ROS) (Butterfield, 2006). Aβ’s toxic effects are largely due to its 
interaction with the ‘receptor for advance glycation end products’ (RAGE) (Yan et al., 1996).  
Aβ-RAGE interactions cause ROS in endothelial, microglial, and neuronal cells, and the 
activation of microglia. Researchers have also found that RAGE expression is elevated in AD 
patients (Karran et al., 2011; Yan et al., 1996), creating a positive feedback loop with Aβ. 
The main tenant of the amyloid cascade hypothesis is that Aβ initiates the disease, and 
then the ROS and tau damage it creates spreads throughout the brain (Figure-7).  Transgenic 
mice lacking Aβ but containing tau do not get AD, and transgenic mice containing Aβ but 
missing tau also do not get AD (Rapoport et al., 2002; Robertson et al., 2007).  It is not clear 
how Aβ formation leads to the formation of neurofibrillary tangles (NTF), however transgenic 
mouse experiments, where mice are engineered to mimic human early-onset FAD mutations in 
APP or PSEN1 (gamma secretase), show that the mutations cause an increase in Aβ formation 
and tau hyper-phosphorylation.  Under normal conditions, tau protein functions to stabilize 
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microtubules, however it can self-assemble in certain neuronal disorders (Avila et al., 2004).  
Hyper-phosphorylated tau no longer acts to stabilize microtubules, so microtubules disassemble 
and the neuronal axons shorten, weakening the synapses (Lovestone & Reynolds 1997). NTFs 
are also present in several other neurodegenerative disorders, including Parkinson’s and 
Hallervorden-Spatz disease (Perl, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-7:  Diagram of the Amyloid Cascade Hypothesis for Alzheimer’s 
Disease.  Note that the formation of  Aβ (yellow, upper left) from the amyloid 
precursor protein (green, upper left) initiates the formation of cellular oxidative 
stress (ROS, orange).  Tau hyper-phosphorylation (red) leads to the disassembly 
of axonal microtubules, weakening the synapse.  (Derived from Adams Review.) 
  
Although a great deal of evidence supports the role of Aβ and tau in AD, how the damage 
spreads to other cells was unknown until this year.  Two main hypotheses exist for the spread of 
the neurodegeneration: 1) the disease spreads from neuron-to-neuron via methods used for 
normal cell communication, or 2) the brain is more resistant to degeneration in some areas than 
others.  Recent evidence supports the former hypothesis. In a study involving mice that 
expressed hyper-phosphorylated human tau only in their entorhinal cortexes, researchers 
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observed the slow spread of NTFs to other regions of the brain over two years. The likely 
explanation for the spread of disease is through neuron-to-neuron interactions (Liu et al., 2012).  
 
Alzheimer’s Mouse Behavioral Tests 
Since the initial 1995 discovery of the AD mouse model carrying the Indiana FAD 
mutation in APP under the control of a PDGF promoter causing Aβ expression in the 
hippocampus and cortex (Games et al., 1995), other transgenic mice have been created carrying 
up to five different APP/PSEN mutations that mimic the disease.  These models have been 
extensively used to study AD progression and to test various therapies, and have been at the 
forefront of scientific research. These mice make suitable models because they show Aβ 
formation in the same regions of the brain as AD patients and initiate neurodegeneration.  Like 
other mice, they are hardy, adaptable, and are small in size, which allows for easy housing and 
relatively large trials.  
Interestingly, the AD mouse models also show behavioral alterations relative to their 
non-transgenic littermates, so these animals allow the testing of potential therapies to improve 
AD behavior (Moran et al., 1995; Nalbantoglu et al., 1997; Chen et al., 2000; Boutajangout et 
al., 2010; Cramer et al., 2012).  The behavioral tests typically measure hippocampal-dependent 
spatial-based learning and memory, as this type of behavior is altered in AD. Various 
environmental stimuli are tested, and the responses of the animals recorded.  Although learning 
and memory cannot be directly observed, researchers can reasonably infer that learning has 
occurred if, for example, a mouse learns to swim towards a submerged platform marked with a 
flag.  
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A number of mouse behavior tests have been designed to test the effects of various drug 
therapies or environmental stresses on AD mice. Such tests include the Morris water-maze test, 
the Y-maze test, the radial arm maze test, the closed field symmetrical maze test, and the object 
recognition test.  In this MQP project, the Morris water-maze test (Morris, 1984) was chosen to 
help evaluate a potential therapeutic drug, because the Morris test has potentially been shown to 
distinguish AD from WT mice (Moran et al., 1995).  In the Morris test, a mouse is placed into a 
round pool of harmless opaque water containing a hidden platform, and trained to locate a visible 
escape platform. To demonstrate learning, the time spent locating the platform is recorded by a 
camera.  Later, the flag marking the hidden platform is removed, and the experiment is repeated, 
recording the time spent locating the unmarked hidden platform.  In other modifications of the 
swimming test, once a mouse has learned the position of an unmarked platform, the platform is 
moved, and the number of trials to learn the new position is recorded (Chen et al., 2000). 
AD mouse research using the Morris water-maze test has yielded numerous research 
outcomes.  Using a Morris water-maze test, transgenic AD mice have been reported to show a 
learning deficit between the ages of 6-12 months without signs of neurological failure or 
abnormal activity (Moran et al., 1995; Nalbantoglu et al., 1997). Another study modified the 
morris water-maze test to allow for long-term and short-term memory processing (Chen et al., 
2000).   In both cross-sectional and longitudinal studies, AD mice showed an age-related deficit 
in the amounts of trials required to learning the series of spatial locations (Chen et al., 2000). A 
study investigating the effects of tau immunotherapy on AD mouse behavior showed that the 
removal of pathological hyper-phosphorylated tau protein in AD mice improved their 
performance in a radial arm maze test, closed field symmetrical maze test, and a novel object 
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recognition test (Boutajangout et al., 2010). More recently, a Morris water-maze test showed 
improvement in hippocampal function of AD mice treated with bexartoene (Cramer et al., 2012).  
 
Neurotrophic Factors 
Neurotrophic factors (NTFs) are a family of diffusible proteins released by neurons and 
supporting cells, such as glia and oligodendrocytes, which play a pivotal role in the survival, 
development, maintenance, repair, and function of neuronal cells. During development, NTFs are 
involved in the formation of the normal synaptic network (Levy et al., 2005) and promote axonal 
development and neuronal survival. Beyond development, NTFs also function to maintain 
specific neuronal functions, such as improving neuronal plasticity during aging and diseased 
states (Murer et al., 2001; Levy et al., 2005; Erickson et al., 2010; O’Bryant et al., 2011; 
Balaratnasingam & Janca, 2012).  
Four main groups of NTFs have been identified in humans (Figure-8): including the 
Brain-Derived Neurotrophic Factor Family (BDNF), Nerve Growth Factor Family (NGF), 
Neurotrophin-3 Family (NT-3), and Neurotrophin-4 Family (NT-4). 
 
 
 
 
 
 
Figure-8:  Diagram of the Four Main Human Neurotrophic Factor Families.  aFGF = acidic 
fibroblast growth factor; ARTN = artenin; BDNF = brain-derived neurotrophic factors; bFGF = 
basic fibroblast growth factor; BMP = bone morphogenic protein; CNTF = cilliary neurotrophic 
factor-1; CT-1 = cardiotrophin-1; EGF = epidermal growth factor; GDNF = glial cell line-derived 
neurotrophic factor; IGF-1 = insulin-like growth factor; IL-6 = interleukin-6; LIF = leukemia 
inhibitory factor; NGF = nerve growth factor; NTF = neurotrophin; NTN = neurturin; OCS-M = 
oncostatin-M; PSP = persephin; TGFβ = transforming growth factor-β (Levy et al., 2005) 
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Following the discovery of the first neurotrophic factor, nerve growth factor (NGF) in 
1952 by Rita Levi-Montalcini (Levi-Montalcini, 1952; Levi-Montalcini, 1953), much research 
has gone into the roles of NTFs in neurodegenerative disease, and their potential use in 
therapeutic treatment. Research into these roles led to the formation of the target-derived 
neurotrophic support concept, which states that a lack of endogenous NTFs in specific neuronal 
populations causes the neuronal death observed in neurodegenerative dementias (Murer et al., 
2001; Levy et al., 2005).  Given that NTFs are often produced in areas affected by early-stage 
AD, NTFs are an attractive candidate for AD therapeutics, and many researchers are 
investigating their role as potential therapeutics for neurological disorders, including AD 
(Barinaga, 1994; Tuszyski & Gage, 1994; Hefti, 1997; Shen et al., 1997; Zuccato & Cattaneo, 
2009).  
Early experimental studies involving the intra-cerebroventricular (ICV) infusion of 
neurotrophic factors suggested that NTF treatment partially reversed the physiological effects 
associated with AD; deficits in spatial memory were observed in the Morris water test in NGF 
‘knockout’ mice and in mice containing antibodies to NGF (Levy et al., 2005), while the 
intranasal administration of the NGF resulted in a complete restoration of neurons in the frontal 
cortex, reduced amyloid plaques, and reversed hyper-phosphorylated tau deposition (Capsoni et 
al., 2002). Reversal of impaired memory or synaptic function has also been observed in studies 
where NTFs were delivered exogenously as pure proteins, or via gene therapy or stem cells 
(Blurton-Jones et al., 2009; Nagahara et al., 2009). Cell death due to exposure to toxins, brain 
trauma, or nerve injury were prevented by pharmacologically delivering NTFs (Jellinger et al., 
2002). 
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Ependymin (EPN) is a neurotrophic factor previously shown to be up-regulated in gold 
fish brain following a series of training and learning events (Benowitz & Shashoua, 1997). EPN 
has multiple functions including facilitating optic nerve elongation and long-term memory 
formation.  Later discovered in mice, monkeys, and humans (Adams & Shashoua, 1994; Adams 
et al., 1996; Apostolopoulos et al., 2001), EPN became a possible AD therapeutic in our lab.  
However, instead of delivering full-length EPN, our lab uses short EPN mimetics (such as CMX-
8933, CMX-9236, or hEPN-1) to facilitate crossing the blood brain barrier.  Our lab has shown 
that goldfish EPN mimetics CMX-8933 and CMX-9236 can induce neuroprotection in vitro 
(Adams et al., 2003) and in vivo (Shashoua et al., 2003; 2004), and can upregulate anti-oxidative 
enzymes SOD-1, catalase, and glutathione peroxidase (Shashoua et al., 2003; 2004).  We have 
also shown that human hEPN-1 can restore human neuronal survival in vitro against an Aβ 
challenge (Stovall, 2006), lowers caspase activation (Kapoor, 2007), lowers tau hyper-
phosphorylation in vitro (Ronayne, 2008), and lowers Cathepsin activity (Donahue & Lobdell, 
2011). 
 
Anti-Oxidative Enzyme: Superoxide Dismutase (SOD) 
 A prevalent theory regarding cell death is the free radical theory of aging, which states 
that reactive radicals result in severe cellular damage, and eventual cell death with continued 
exposure (Beckman & Ames, 1998; Venarucci et al., 1999; Allen & Tresini, 2000).  In 
Alzheimer’s, Aβ causes a cellular increase in reactive oxidative species (ROS). Accordingly, the 
accumulation of ROS results in the brain’s inability to produce anti-oxidative enzymes, such as 
catalase (CAT), glutathione peroxidase (GPX) or superoxide dismutase (SOD) (Smith et al., 
2000; Shahoua et al., 2004).  
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 SOD catalyzes the dismutation of superoxide anions to hydrogen peroxide. Hydrogen 
peroxide is then broken down to molecular oxygen and water by GPX or CAT (Sun and Chen, 
1998). All three enzymes serve to protect the cell against free radicals and reactive oxygen. 
Studies have shown that over-expression of SOD make mouse models resistant to cerebral 
anoxia (Chan et. al., 1998; Sheng et al., 1999; Li et al., 2001), as SOD serves a neuroprotective 
function.  Previously, our lab showed that neuroblastoma cells show increased SOD levels 
following in vitro treatment with hEPN (Parikh, 2003). Our project will test whether the human 
NTF hEPN affects SOD levels in transgenic AD mouse models, and whether the potential SOD 
changes correlate with behavioral improvements. 
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PROJECT PURPOSE 
 
 Our laboratory previously showed that treatment of cultured human SHSY neuronal cells 
in vitro with a short neurotrophic factor mimetic increases neuronal cell survival and increases 
cellular levels of anti-oxidative superoxide dismutase (SOD-1). The purpose of this project was 
to determine whether intraperitoneal treatment of transgenic AD mice with this short peptide 
improves learning or memory, and if so, does the improved behavior correlate with an increase 
in the cellular levels of SOD.  A Morris water swimming test, that requires cortical and 
hippocampal function, was used to potentially distinguish WT and AD mice treated with vehicle 
or peptide drug.  Immunoblots were used to assay the levels of anti-oxidative SOD-1 in the brain 
to see if those levels correlated with behavior. 
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METHODS 
 
In Vivo AD Mouse Model 
Hemizygous male Alzheimer’s mice were purchased from The Jackson Laboratory 
(strain #006554).  This strain is 5X transgenic for human amyloid precursor protein (APP) and 
presenilin (PSEN) mutations.  The Tg males were crossed with B6 WT females (strain #100012), 
so that approximately 50% of the offspring were AD and 50% WT.  The pups were aged to 9 
months, an age at which senile plaque formation is prevalent.  Two WT sentinel mice were sent 
to Charles River Labs for histology testing to prove the colony was disease free.  The aged mice 
were then dosed twice per day for two weeks i.p. with 60 mg/kg hEPN NTF mimetic, after which 
mice were sent to PsychoGenics (Tarrytown, NY) where the morris water-maze tests were 
conducted.  Following the tests, the mice were euthanized, and the brains and tail sections were 
harvested and sent back to WPI and stored at -80ºC. 
 
Morris Water-Maze Test 
Prior to the test, mice were examined, weighed, and handled to minimize manipulation-
associated stress, and to confirm test subjects were healthy and suitable for testing. A circular 
plastic maze (120 cm diameter) that contained external pool cues and 74-76
o
C opaque water was 
used. The maze was divided into four quadrants marked by distant spatial cues. The water was 
made opaque through the addition of a non-toxic paint to hide an escape platform located 25 cm 
below the pool rim (0.5 cm below the water’s surface). Mouse behavior was monitored using a 
video camera placed above the maze. Analysis was conducted using the Watermaze tracking 
package (Coulbourn, USA).  
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During day 1 and 2, mice were handled for 60 seconds to reduce stress associated with 
manipulation and testing. At the end of day 2, subjects were introduced to shallow water (74-
76
o
C) for 20 seconds. Behavioral testing began on day 3 and lasted for three consecutive days. A 
platform marked with a visible cue just above the surface of the water was placed roughly half-
way between the center of the maze and the wall, in the center of one of the quadrants. Mice 
underwent six training trials, spaced at roughly 20 minute intervals.  
During day 6 through 10, the visible cue at the platform was removed, and mice were 
required to locate the hidden unmarked platform during four trials, spaced at roughly 20 minute 
intervals. The platform location remained consistent throughout teach trial, requiring the animals 
to rely on the initial spatial cues to learn the platform location. 
The time it took to locate each platform and the total distance traveled was recorded for 
each sample. Phase 1 of the trial (day 3-5) enabled a measurement of the animal’s ability to 
locate and climb onto the flagged platform. Phase 2 of the trial (day 6-10) served to measure the 
animal’s memory of that location. Fifty-six mice were tested in two cohorts. Tests were 
performed during animal light cycle phases, and without knowing whether the mouse  was AD or 
WT.  
 
 
Genotyping AD Mouse Tissues 
The genotype of each mouse was determined by PCR for APP and PSEN transgenes in 
tail section DNA.  DNA was isolated by phenol extraction techniques, then amplified with 
primers for human APP or PSEN (see below).  
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Phenol Extraction from Mouse Tails 
DNA was extracted by first removing 0.5 mm of tail section from the tail segment 
provided to us by PsychoGenics, and placing it in a 1.5mL eppendorf tube. A 0.5 mL volume of 
freshly made DNA digestion buffer with proteinase K (50 mM Tris-HCl pH 8.0, 100 mM EDTA 
pH 8.0, 100 mM NaCl, 1% SDS, 0.5 mg/mL fresh proteinase-K powder) was added. Samples 
were incubated overnight with gentle shaking at 50-55
o
C. Tubes were spun briefly to remove the 
solution from inside the cap, then a 0.7 mL volume of neutralized phenol/chloroform/isoamyl 
alcohol (25:24:1) was added. Tube was mixed for 5 minutes on clinical rotator. Following a 5 
minute microfuge at top speed, 0.5 mL of the upper phase was transferred to a new microfuge 
tube. A 1 mL aliquot of 100% ethanol at room temperature was added. The tube was inverted 
until DNA precipitate developed. Tube was spun in a microfuge for 5 minutes at maximum 
speed, and the supernatant was carefully removed and discarded. 0.5-1.0 mL of 70% ethanol was 
added, and the sample was inverted numerous times to wash the DNA.  Following a 5 minute 
microfuge at maximum speed, the supernatant was carefully removed and discarded. Tubes were 
spun again to remove any remaining ethanol solution. The sample was left overnight to dry at 
room temperature. The following day, DNA was resuspended by adding 200 μL of 1X TE buffer 
and incubating the sample for 15 minutes at 55
o
C to dissolve the DNA.  The samples were 
diluted 1:100 in TE buffer, for a final yield of 20-50 μg DNA. 
 
PCR 
Master mixes (400 µL) were prepared for ten APP and PSEN genotyping reactions (50 
μL per reaction) according to the following table: 
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APP: 
 237 μL of dH2O 
 50 μL of 10X PCR buffer 
 25 μL of 50 mM MgCl2 
 10 μL of 10 mM dNTPs 
 25 μL of 20 μM APP-3610 
 25 μL of 20 μM APP-3611 
 12.5 μL 20 μM Ctrl-8744 
 12.5 μL of 20 μM Ctrl-8745 
 3 μL of 5 U / μL Taq 
Polymerase 
 
PSEN: 
 196 μL of dH2O 
 50 μL of 10X PCR buffer 
 25 μL of 50 mM MgCl2 
 10 μL of 10 mM dNTPs 
 33 μL of 20 μM PSEN-1644 
 33 μL of 20 μM PSEN-1645 
 25 μL 20 μM Ctrl-7338 
 25 μL of 20 μM Ctrl-7339 
 3 μL of 5 U / μL Taq 
Polymerase 
 
 
Master mix (40 µL) was aliquoted into the tubes, then 10 µL of tissue lysate was added to 
make a 50 µL reaction.  The tubes were subjected to PCR as follows:  Step 1: 94°C for three 
minutes; Step 2: 94°C for 30 seconds, 52°C for one minute, 72°C for one minute; Repeat Step 2 
for 35 cycles; Step 3:  72 °C for two minutes; Step 4: 4 °C infinitely.  Following PCR, 5.5 µL of 
10X Sample Buffer (0.025% xylene cyanole, 100 mM EDTA pH 8.0, 50% glycerol) was added 
to each 50 µL reaction, then 10 µL was loaded onto a 2.5% agarose gel in 1X TAE buffer 
containing 1 µg/mL (final concentration) Ethidium Bromide.  The first lane was loaded with 10 
µL of 100 bp DNA ladder (0.5 µg).  Gels were electrophoresed at approximately 60 V for 1.5 hr, 
then were photographed by UV trans-illumination. 
 
Brain Whole Cell Lysates 
A small slice of brain tissue (0.1 g) was combined with 1 mL of Complete Lysis Buffer 
[20 mM HEPES pH 7.9, 10 mM KCl, 300 mM NaCl, 1 mM MgCl2, 0.1% Triton X-100, 20% 
glycerol, 0.5 mM DTT (freshly added; Gibco), and 0.5 mM PMSF (freshly added; Sigma)] in a 
1mL dounce homogenizer. The sample was homogenized by at least ten up-and-down strokes.  
Homogenates were transferred to a 1.5 mL eppendorf tube and placed on ice.  The sample was 
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microfuged for 5 minutes at 4
o
C, at maximum speed to pellet cell debris. Aliquots of supernatant 
were stored at -80°C. 
 
SOD & Tubulin Immunoblots 
 The Bradford Assay was used to determine the total cellular protein concentrations of each 
tissue lysate.  Necessary volumes for 5 µg per lane for tubulin or 2 µg per lane for SOD were 
mixed with 1X protein sample buffer (0.125 M stacking gel buffer, 4% SDS, 20% glycerol, 10% 
β- Mercaptoethanol, and 0.1% bromophenyl blue powder) to make a total load volume of 10 µL. 
A 20 µL load volume  of 1X sample buffer (10 µL)and Kaleidoscope Pre-Stained Standard (10 
µL, Bio-Rad) was also made.  Samples were boiled for two minutes to ensure protein 
denaturation and an even coating with the SDS.  Samples were then loaded onto gels with a 
lower gel containing 10% polyacrylamide, 0.38 M resolving buffer, 0.1% SDS, 0.1% ammonium 
persulfate, and 0.05% TEMED.  The upper gel was composed of  5% polyacrylamide, 0.125 M 
stacking gel buffer, 0.1% SDS, 0.1% ammonium presulfate, 0.1% TEMED.  The protein 
electrode buffer used included 25 mM Trizma Base, 0.192 M glycine, and 0.1% SDS.  Prior to 
sample loading, gels were pre-run for 15 minutes at 150 volts to equilibrate with the buffer, then 
electrophoresed for roughly 150 volts for three hours.  
 Following electrophoresis, the protein was electroblotted to nitrocellulose membrane (0.45 
μm pore size, Whatman) in pre-chilled transfer buffer (48 mM Trizma Base, 39 mM glycine, 
0.037% SDS, 20% methanol).  Transblotting occurred at 50 volts for two hours at 4°C with 
stirring.  Membranes were then submerged in PBS-CT western blocking solution (1% casein, 1X 
PBS, 0.2% Tween-20) with the membrane protein-side up. The membrane was blocked at room 
temperature for at least one hour with rocking. 
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 Primary antibody incubations for SOD contained 25 μL of 90 mg/ml rabbit anti-bovine 
SOD-1 (Rockland) added to 50 mL of fresh blocker solution (1:2000 dilution), to give a final 
concentration of  45 μg/mL.  Primary antibody incubations for β-tubulin contained 25 μL of 500 
μg/ml anti-β-tubulin (Imgenex, IMG-5810A) mixed with 50 mL of fresh blocker solution 
(1:2000 dilution) to give a final concentration of 0.25 μg/mL. Membranes were incubated with 
primary antibody for two hours at room temperature with rocking, then washed twice for two 
minutes with PBS-Tween (1X PBS, 0.05% Tween) using vigorous shaking on a gyratory shaker. 
Secondary antibody incubations included a 0.4 mg/mL final concentration of goat-anti-rabbit-
HRP (Pierce) and a 0.5 mg/mL final concentration Streptavidin-HRP (Pierce; 1:1000 dilutions of 
glycerol stocks; 25 μL of secondary antibody added to 25 mL blocker).  Secondary antibody 
incubations were performed for two hours at room temperature with gentle shaking. Membranes 
were then washed three times with PBS-Tween for two minutes with vigorous shaking on a 
gyratory shaker, then rinsed briefly with 1X PBS before detection. 
 SuperSignal West Pico chemiluminescent substrate (Pierce) was used to detect protein 
presence by combining equal amounts of Stable Peroxidase Solution and Luminol/Enhancer 
Solution just prior to use, and incubating the membrane at room temperature in the fresh 
substrate solution for five minutes with the protein-side facing upward. The substrate was then 
allowed to drip from the membrane without drying, then placed between two clear plastic sheets 
(Gibco) in a film cassette.  Tubulin blots were exposed to Biomax XAR-5 film (Kodak) for four 
minutes, and SOD blots for four seconds.  Film was developed automatically in the Kodak 
M35A X-Omat Processor. 
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Human SH-SY5Y Cell Culture 
Human SH-SY5Y neuroblastoma cells (commonly termed SHSY) were obtained from 
medium-adapted liquid nitrogen stocks previously obtained from ATCC and prepared in our 
laboratory.  Culture medium contained 500 mL DMEM-F-12 (ATCC), 50 mL of FBS (Gibco, 
ATCC, or Hyclone) to give a final concentration of 10%, and 0.275 mL of 10 mg/mL 
gentamycin (BioWhittaker) to give a final concentration of 5 μg/mL.  The DMEM-F-12, FBS, 
and gentamycin were mixed in the 500 mL medium bottle, then filter sterilized.  Medium was 
stored at 4°C.   
To thaw our lab’s SHSY cells from liquid nitrogen storage, the cells were placed in a 
37°C water bath for one to two minutes until completely thawed, then carefully re-suspended and 
transferred into a T-25 flask where 5 mL of pre-warmed medium was added. The plate was 
placed in a 37°C + 5% CO2 humidified incubator. Following 24 hours, old medium was replaced 
with fresh pre-warmed media. 
Cultures were fed every 3-4 days until the flasks achieved approximately 80% 
confluency, at which point cultures were split 1:2 into new flasks. To feed cultures, the old 
medium was aspirated and replaced with 4 mL of fresh, pre-warmed medium. To split cultures, 
the old medium was aspirated and replaced with pre-warmed medium (8 mL for T-25), and the 
flask scraped to release the cells from the floor of the flask. The cells were then re-suspended and 
pipetted into new flasks (4 mL for T-25).  
To freeze SHSY cells, confluent T-75 flasks were scraped and the cell suspension 
centrifuged for five minutes at 6500 rpm. The supernatant was aspirated, and 1 mL of pre-
warmed freezing medium (Gibco) was added. The cells were re-suspended, pipetted into a 
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freezing vial, and stored at -80°C in a Styrofoam® rack for insulation to slow the freezing 
process. After 24 hours, the cells were moved to liquid nitrogen storage. 
For plating experiments, 80% confluent T-25s (2 plates) were split and plated onto four 
T-25s. For Aβ treatment conditions, Yankner peptide (Tocris; see below) was introduced to 
flasks at 20 µM (80 µL of 1 mM stock per 4 ml medium).  For hEPN treatment conditions, 
hEPN-1 peptide (BioTherapeutix, Inc.) was introduced to flasks at 150 µM (160 µL of 3.75 mM 
stock per 4 ml medium). Untreated, control flasks generally reached approximately 80% 
confluency after 72 hours, at which point cells were subjected to morphology and trypan blue 
exclusion cell counts (see below) and harvested by scraping. 
 
Yankner Peptide 
Human Yankner peptide powder (Aβ25-35) was purchased from Tocris Bioscience (#1429, 
Batch 5B).  1 mM stock solutions were prepared by dissolving 1 mg of powder (943 nmol) per 
0.94 mL of 1 mM sodium bicarbonate.  Stock solutions were stored at -20°C. The Yankner 
peptide was used at a final concentration of 20 μM (80 µL of the 1 mM stock per 4 ml of 
medium) in human SHSY cell culture, which was previously shown in our lab to produce 
neurotoxic effects. 
 
hEPN-1 Neurotrophic Factor 
Several human ependymin–1 (hEPN-1) peptides containing the same amino acid 
sequence in different salt conditions were provided by BioTherapeutix, Inc. (Brookline, MA) or 
CS Bio Company (Menlo Park, CA).  Peptides were received as dry powders and stored at  
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-20°C.  For plating experiments, hEPN-1 peptides were prepared as 3.75 mM stock solutions by 
dissolving 1 mg of peptide per 1 mL of filtered DMEM-F-12 medium without serum.  160 µL of 
the 3.75 mM stock was added to 4 ml medium in a T25 flask to make a 150 μM final 
concentration. 
 
Cell Morphology Counts 
Three representative regions of each experimental flask were imaged at 72 hours post-
plating by a Leica inverted microscope and camera attachment at 20x magnification. Images 
were used to count cells with free stellate morphologies, physically networked morphologies, 
and free non-stellate (lacking protrusions, or “balled up”) morphologies, as well as total cells per 
viewing field. Counts from all three representative regions of flasks were averaged to provide 
final morphology estimates as a percentage of total cell counts. 
 
Trypan Blue Exclusion Viability Assay 
Cell suspensions harvested from experimental flasks were vortexed, and 10 µL aliquots 
of suspension were transferred to a 1.5 mL eppendorf tube. Each aliquot was vortexed and 
pipetted onto a clean microscope slide with an equal volume of 0.4% Trypan Blue (Gibco), and 
the solution was mixed using a pipette tip and spread to create an area of about 1cm by 1cm. 
Three representative regions of each slide were imaged (as described above), and images were 
used to count total viable (Trypan Blue-excluding) and non-viable cells. Counts from all three 
representative images were again averaged to provide final viability estimates as a percentage of 
total cell counts.  
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RESULTS 
 
 
 The purpose of this project was to identify a behavioral test that was effective in 
distinguishing AD from WT mice, to determine whether hEPN-1 treated mice perform better in 
the test, and to determine whether the behavior correlates with changes in brain SOD levels.   
 
In Vitro Alzheimer’s Model with Aβ and hEPN 
 Our lab previously showed that adding A to human SHSY cells in culture is an effective 
in vitro model of AD, as the addition increases cell death (Stovall, 2006), tau hyper-
phosphorylation (Ronayne 2008), apoptotic TUNEL staining (Ronayne 2008), and caspase-3 
levels (Kapoor, 2007).  When simultaneously adding hEPN with the A, these effects all 
decreased.  This in vitro system was used to validate the drug used in vivo.   
 
Trypan Blue Exclusion Test of Cell Viability 
To test whether the hEPN therapeutic could rescue function in neuronal cells, an in vitro 
assay was set up using an SHSY neuronal cell line. At time of splitting, one flask of cell culture 
received 20 μM A, another received A + hEPN1 BTX-639, and a third flask was left untreated 
as a control. When the control flask reached 80% confluency, the cells were treated with trypan 
blue staining to monitor cell viability.  Dead cells cannot exclude the dye so appear dark blue.  
Viable cells exclude the dye and appear white.  hEPN was effectively shown to reverse the 
effects of A (Figure 9).  Compared to the control flask, the A-treated flask showed minimal 
neuronal growth, and the addition of the hEPN resulted in restoration of the cells. A cell count 
analysis (Figure-10) showed that the simultaneous addition of A + hEPN was able to increase 
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cell viability by 30%, bringing the total cell viability to near normal conditions (normal=73%, 
hEPN+A = 68%). Thus, this data illustrates that the hEPN therapeutic is effective in vitro. 
 
 
  Untreated   A   A + hEPN 
 
Figure-9: Trypan Blue Analysis of Human SHSY Cell Viability. The three 
photomicrographs show an untreated (control), A treated (20 µM), or A (20 µM) and 
BTX-639 (150 µM) treated flask.  Cells were harvested, stained with Trypan blue, and 
viewed under 20X magnification.   
 
   
 
Figure-10: Cell Viability Analysis. The bar graphs represent the percent 
viable/non-viable cell counts from the in vitro cell culture experiment. Black: 
viable, gray: non-viable.  
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Mouse Genotyping 
Because hemizygous AD males were bred to WT females, about 50% of the offspring are 
AD and 50% WT. The genotype differences cannot be visibly distinguished, so genotyping was 
performed on tail section DNA by PCR for the presence of the human APP and PSEN 
transgenes.  Genotyping was performed on 52 mice; APP and PSEN transgenes were measured 
separately, then the results were compared (Figure 11).  
 
 
 Figure-11: Mouse Genotyping.  Tail section DNA for 52 mice was isolated and amplified by PCR for 
human APP or PSEN transgenes. Amplified DNA was electrophoresed on 2.5% agarose gels and 
photographed with UV trans-illumination. A-C) APP genotyping for 52 mice.  D-F) PSEN genotyping for 
52 mice.  Main amplicon (APP or PSEN) is the strong band in the middle. The lower band represents the 
internal control for each reaction.  Mice that showed positive for APP mutations were also positive for 
PSEN mutations. 
 
 
Figure-12 shows a summary table of the 36 mice chosen by PsychoGenics for the morris 
swimming test.  They divided their mice into two cohorts.  Rougly 20% of those tested in the 
first cohort were AD mice, while in the second cohort an estimated 56.25% of mice were AD. 
A B C 
A B C 
D E F 
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Figure-12: Summary Table of Mouse Genotyping For the 36 Mice Tested by PsychoGenics. 
PsychoGenics performance test data included 36 of the original 52 genotyped mice. For performance data 
analysis, mice 1-4, 8, 10, 15 17, 21-32, 35, and 36 were used. Mice were divide into two cohorts, the first 
of which received a placebo (vehicle) while the second received the hEPN therapy.80% of mice in the first 
cohort were WT. In the second cohort, 43.75% of mouse subjects were WT. A) Cohort 1, Mouse subjects 
1-20.  B) Cohort 2, Mouse subjects 21-36.  
 
 
Morris Water Maze Test of Mouse Cognitive Performance 
Due to the uneven distribution of AD and WT mice within each cohort, the number of 
mice for data analysis was reduced. The first four WT mice in the first cohort were used for 
performance analyses, to match the number of available AD mice. In the second cohort WT mice 
represented a smaller percentage of the group, containing only 7 mice. Thus for data analysis, 
only the first seven AD mice were used.  
As described above, mouse subjects were divided into two cohorts and observed using a 
camera placed above the plastic maze. Mice were trained to locate a hidden platform placed 
within one of the quadrants, which was located 0.5cm below the surface of the water. In the first 
three days of testing, the platform was marked with a visible flag cue. The visible cue was 
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removed during the next five days of testing.  The time it took for each subject to remember to 
locate the hidden platform and the distance traveled was recorded.  
When subjects were required to locate  a marked platform, vehicle-treated AD mice 
located the platform between 32-46 seconds on day 1, and 22-30 seconds on the day 3 (Figure-
13, A) (averaging 40 seconds on day-1 and 25 seconds on day-3, as each mouse typically did 
better each day) (Figure-13, B). In the same test, WT mice located the platform within 7-14 
seconds on day-1 and 5-8 seconds on day-3 (Figure-13, A) (averaging 10 seconds on day-1 and 
roughly 6 seconds on day-3 (Figure-13, B).  Similar results were obtained for unmarked 
platform tests. AD mice took on average 25 seconds to locate the hidden platform on the final 
day of testing, while WT located the platform in roughly 10 seconds (p = 0.05, Figure-13, D). 
Considering the significance of the data obtained (p < 0.05) as well as  the clear time gap 
between AD and WT groups, the morris water maze test was identified as an accurate test for 
distinguishing AD and WT mice.  
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Figure-13: The Morris Water Maze Test Effective Distinguishes WT from AD Mice. After being 
acclimatized to handling and water, mice were tested over a three day period using a marked platform and 
5-day period using an unmarked platform. Researchers conducted the test blind, thus they did not know 
which mice were AD or WT. Following genotyping, behavioral test results were matched with genotyping 
results. Platforms were marked with a flag, visible above the water. A) Time for each vehicle-treated mouse 
subject to locate marked platform over three days. The flag was removed in unmarked situations. B) 
Average time for AD and WT mice to located marked platform. C) Time for individual vehicle-treated 
mouse subjects to located unmarked platform. D) Average time for vehicle-treated mice to locate unmarked 
platform over 5 days. 
 
 
After establishing that the morris water maze test provided an accurate distinction 
between AD and WT mice, analyses were done to determine the effectiveness of the hEPN 
treatment on AD mice. For this, vehicle and hEPN-treated AD mice were compared (Figure-14).  
Data showed that on average vehicle-treated AD mice took longer to locate marked and 
unmarked platforms than hEPN-treated AD mice (p = 0.01). hEPN treated mice took roughly 12 
Unmarked Platform 
Marked Platform 
A B 
C D 
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seconds to locate marked and unmarked platforms on final testing days (Figure-14, C, F). 
Vehicle-treated mice, needed approximately 25 seconds to located marked and unmarked 
platforms on day 3 or day 5 of each test (Figure-14, C, F). Noting that the time for hEPN treated 
AD mice to locate a hidden platform approached the time required by WT mice, the therapeutic 
effectively improves AD mouse cognitive performance at the 60 mg/kg dose administered. 
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Figure-14: hEPN is an Effective AD Treatment.  Morris water maze test results were compared between 
vehicle-treated AD mice and hEPN-treated mice. The time to located marked and unmarked platforms were 
recorded and compared. The left column displays results for vehicle and hEPN-treated mice locating a 
marked platform. The right column displays results for vehicle and hEPN-treated mice locating an 
unmarked platform. A) Mouse subjects 8, 10, 15 and 17 received a vehicle  treatment, and took 32-46 
seconds to locate the marked platform on day 1. Mice located the marked platform in roughly 25 seconds 
on day  3. B) Time for hEPN-treated mice (21, 22, 23 ,25) to located marked platform.  C) Average time 
for vehicle-treated and hEPN-treated mice to located marked platform over three days D) Time to locate 
unmarked platform for vehicle-treated AD mice. E) Time to located unmarked platform for AD hEPN-
treated mice. F) Average time for vehicle and hEPN treated mice to located unmarked platform. 
** 
** 
** 
** 
** 
* * 
* 
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Considering AD mouse performance was improved by the drug, it was hypothesized that 
the drug may also improve WT mouse performance. In a comparison of the effects of hEPN 
treatment on WT mice (Figure-15), it was found that hEPN1 treatment enhances WT cognitive 
performance. In marked and unmarked platform situations, hEPN-treated mice located the 
platform 1-3 seconds faster than vehicle treated mice on the final testing day (Figure-15, A, B). 
Overall, by the final testing day treated mice also traveled approximately 110 cm less to locate 
the marked platform (Figure-15, C), and roughly the same distance to the unmarked platform 
(Figure-15, D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-15: hEPN Slightly Enhances WT Mouse Performance. WT mouse performance was improved 
by hEPN treatment. Analysis was done comparing hEPN-treated and vehicle-treated WT mice. Altogether, 
WT mouse performance was improved by treatment with hEPN. A) Average time for mouse subjects to 
located marked platform. B) Average time for mouse subjects to located unmarked platform. C) Average 
distance traveled by mice to marked platform. D) Average distance traveled by mice to unmarked platform.  
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All mice, WT or AD, typically improve their swimming with each training.  When 
reviewing the percent improvement in time or distance traveled over three (for marked platform) 
or five days (for unmarked platform), hEPN was further shown to improve both the time it takes 
for a mouse subject to located a platform and the distance traveled by each subject to a particular 
platform. Among WT or AD mice, cognitive performance increased between vehicle-treated 
subjects and hEPN treated subjects (Figure-16). Among vehicle-treated subjects, in general AD 
mice showed less performance improvement than WT mice (Figure-16, A, C). Among the hEPN 
treated mice, the greatest performance improvement was observed in WT mice (Figure-16, B, 
D). All data were analyzed using a standard t-test and standard error.  
 
 
Figure-16: hEPN Enhances WT & AD Mouse Performance. The time it took for WT and AD mice to 
locate a platform on day 1 and day 5 was compared to determine the overall performance improvement for 
each subject. The percent improvement for each subject was averaged among WT and AD groups. It was 
found that in all situations, mouse cognitive performance improved with treatment. A) Percent 
improvement in time to locate marked platform.AD mice showed less performance improvement than WT-
hEPN treated mice. AD vehicle-treated mice showed greater performance improvement than WT mice. B) 
Percent improvement in time to located to unmarked platform. AD mice showed less improvement than 
WT mice among vehicle and hEPN treated mice. C) Percent improvement in distance traveled to marked 
platform. AD mice showed less improvement than WT mice given vehicle and hEPN. D) Percent 
improvement in distance traveled to unmarked platform. AD vehicle treated mice showed less 
improvement than WT mice, however hEPN-treated AD mice showed more improvement than WT hEPN-
treated mice.  
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SOD Immunoblots 
 
 Determining that hEPN treatment significantly improved AD mouse performance, 
preliminary investigations into the cause of the improved behavior were conducted.  Because 
ROS is well known to increase in AD, it was hypothesized that cellular levels of SOD, an 
enzyme known to reduce ROS, would be greater in WT mice that show lower ROS. In line with 
previous research done in our lab showing that SOD levels increased with treatment of hEPN in 
vitro, a similar increase in SOD levels was expected in the mouse model.  
To determine whether the in vivo i.p. hEPN therapy influenced the brain levels of SOD, 
immunoblots using extracts from AD vehicle (n=4) and AD therapy (n=4) mice brains were 
performed. Once brain tissue was lysed, it was separated by PAGE and blotted onto a 
nitrocellulose membrane. It was then probed using antibodies for both SOD (55 kDa) and tubulin 
(16 kDa). Scion Image software was used to analyze the mean optical densities (data not shown), 
which indicated that AD therapy mice showed a slight decrease in SOD levels in one set of 
results, although insignificant (Figure-17). This result was different from our stated hypothesis 
that SOD levels will increase with hEPN treatment. In the process of standardizing SOD and 
tubulin levels, it was observed that when SOD was standardized relative to tubulin, the tubulin 
levels actually strongly fluctuated between the samples. This might be the effect of 
hyperphosphorylated tau protein destabilizing the tubulin structures in the A cascade, thus 
tubulin might not be the best marker to normalize the data against.  Although hEPN might lower 
SOD levels in vivo slightly, there does not seem to be a major effect.  
  
 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-17: SOD Immunoblots for SOD and Tubulin. A. Immunoblot results 
of AD vehicle (n=4) and AD therapy (n=4) mice. Protein was detected by 
SuperSignal West Pico chemiluminescent substrate (Pierce), and exposed to 
Biomax XAR-5 film (Kodak) for four minutes for tubulin or one second for 
SOD. Film was developed automatically in the Kodak M35A X-Omat 
Processor. 
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DISCUSSION 
 
 
 This project extended our lab’s previous in vitro and in vivo AD experiments by 
investigating the effects of neurotrophic factor treatment on AD mouse behavior.  Previous 
research showed that treating human neuroblastoma cells in vitro with goldfish EPN partially 
restored cell viability (Stovall, 2006) and decreased tau hyper-phosphorylation and TUNEL 
staining (Ronayne, 2008) following an Aβ threat. Furthermore, our lab previously showed that 
cellular levels of antioxidant superoxide dismutase-1 (SOD-1) increased in vitro with hEPN1 
treatment.  This project extended these studies by examining the effects of hEPN in a 5X 
transgenic mouse model. A particular focus was placed on SOD as a potential cause of improved 
cognitive performance.  
 
In Vitro Alzheimer’s Model 
An in vitro neuronal cell viability assay using trypan blue staining has shown that hEPN 
restores function in cells treated with toxic A.  The assay performed in this project demonstrates 
that the solubilized A is indeed toxic to human neuronal cells, and that the cells can be rescued 
by the coapplication of hEPN + A.  It would have been also interesting to extend these 
experiments to add the hEPN at specific time points after the cells have been treated with A to 
determine how late the NTF can rescue the programmed death pathway. This is important to 
consider since studies have shown that A begins to accumulate in the brain of an AD patient 
years before the presence of symptoms. 
 
 
 47 
 
Morris Water Maze Test 
To date, researchers have tried a variety of behavioral assays to characterize and 
differentiate WT and AD mouse behavior, including the Y-maze, Rotarod, Elevated Plus-Maze 
test, and others. However, many of the tests show minimal differences between AD and WT 
mouse activity, suggesting the tests cannot easily distinguish the two groups. One particular 
study, that involved the use of transgenic female mice homozygous for human β-APP, showed 
the Morris test to be effective in distinguishing AD and WT mice (Moran et al. 1995). Our 
research shows that the Morris test can accurately distinguish 5X transgenic AD and WT mice at 
8 months of age (p < 0.05). Furthermore, it shows that AD and WT mouse performance 
improves with treatment of hEPN-1 (p = 0.01).   
 
SOD 
 It is known that SOD is typically up-regulated during cellular stress. We were interested 
in determining whether hEPN affects the levels of SOD in AD mice, and hypothesized that 
hEPN will increase SOD levels. Experimenting with 5X transgenic, 8-month old AD mice, we 
did not observe any significant changes in SOD levels when comparing AD vehicle to AD hEPN 
mice. This result may indicate that hEPN does not affect the cellular stress pathway, or that the 
hEPN1 dose and time used did not affect SOD levels, but more repeats of this experiment should 
be performed to make this conclusion. Previous studies in the lab have associated hEPN with 
increases in the levels of catalase and glutathione peroxidase, enzymes that function similar to 
SOD. 
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Future Recommendations 
Currently, the cause of improved cognitive performance in mice as a result of hEPN-1 
treatment is unknown.  Future studies should involve a repeat of the previous behavioral tests 
using an appropriate pre-scoring mechanism to assess overall swimming capability and 
potentially measure AD and WT nest building ability.  The study should include all bred mice in 
the data, to increase statistical significance.  Upon repeat of the test and data analysis, a series of 
in vitro assays should be undertaken to understand the mechanistic nature of Aβ-induced cell 
death.   Although SOD did not appear to be a major player in observed improvements in spatial 
learning and awareness, a variety of other brain proteins could be involved, many of which have 
been shown to be upregulated with hEPN treatment previously in our lab, such as anti-oxidant 
enzymes glutathione peroxidase (GPX) and catalases (CAT), known to serve a neuroprotective 
function in models for cerebral ischemia (Smith et al., 2000; Shashoua et al., 2001, 2003, 2004; 
Adams et al., 2003), as well as cellular inhibitors of apoptosis (cIAPs), known to inhibit caspases 
and pro-apoptotic proteins. Our lab previously showed cIAPs are elevated post-treatment with 
hEPN (Rawal, 2010). Our lab’s working hypothesis regarding the mechanism by which Aβ 
affects neuronal cells can provide a variety of other potential targets for investigation (Figure-
18). 
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Figure-18: Summary of Our Lab’s Previous Work. The diagram presents a combination of known 
aspects of the amyloid cascade hypothesis and findings made in our lab involving treatment with hEPN. 
Inaccurate cleavage of the amyloid precursor protein receptor (APP) by γ- and β-secretases initiates the Aβ 
cascade, through the production of a 40-42 amino acid toxic protein (Aβ). Our lab found that the Aβ 
peptide both increased caspase-2 and caspase-3 (Kapoor, 2007), and tau hyper-phosphorylation, as well as 
TUNEL staining (Ronayne, 2008). Overall Aβ was shown to increase cell death, while hEPN treatment 
partially restored theses effects. A portion of the hEPN mechanism involves the up-regulation of cellular 
inhibitors of apoptosis (cIAPs) (Rawal, 2010), potentially through the use of a separate receptor. Cathepsin-
D, a lysosomal aspartic protease, is also involved in the cell death pathway, though its role is still unclear 
(Donahue and Lobdell, 2011).  (Derived from Adams Review; Donahue & Lobdell, 2011). 
 
The observed changes in tubulin levels in AD mice, when SOD levels appeared to remain 
constant between mice, is likely due to the effects of Aβ on tubulin polymerization. For this 
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reason, tubulin is likely an inaccurate housekeeper for AD mice. Investigations into the degree of 
polymerized tubulin in WT, Aβ-treated, and Aβ+hEPN-treated cells should be conducted to 
better understand the physiological effects of Aβ on tubulin and cellular shape. A more accurate 
housekeeper molecule should also be identified and used in future investigations.  
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